Key facts
- Healx’s last known valuation is $275.9M (Aug 2024).
- It has raised $133.7M; the latest was Later Stage VC ($2.0M) in Jul 2025.
- Notable investors include Global Brain, Intel Capital, Atomico, Balderton Capital, Cambridge Angels — 32 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 32 names
- ·Watchlist + deal alerts for Healx
- ·The full record, as it builds
Funding rounds
No funding rounds for Healx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Healx
Developer of artificial intelligence-driven drug discovery technology designed to create treatments for rare diseases. The company offers a combination of frontier machine learning technology and drug discovery expertise, enabling clients to accelerate the development of novel treatments and improve the success rate for addressing the unmet needs of rare disease patients worldwide.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2014
- Employees
- 69
- Website
- healx.ai/
- Ownership
- Privately Held (backing)
Healx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Healx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Healx in its N-PORT filings yet. We sweep new filings monthly.